Guidance for 2018 placements of ePlex respiratory testing systems is lower than analysts’ estimates, but the firm communicated remedies for adoption challenges.
On a conference call following the release of the earnings, the firm's CEO guided for lower 2018 ePlex placements than had been expected by analysts.
The company said 571,000 people were screened for colon cancer with its noninvasive Cologuard test in 2017.
Luminex said that its MDx sample-to-answer portfolio grew 31 percent over the prior-year quarter and generated $12.9 million.
Overall, revenues were up 8 percent. In the diagnostics segment, molecular product sales were driven primarily by continued strength across Aptima women's health products.
Within the centralized and point-of-care solutions business, integrated serum work area solutions drove growth with immunodiagnostics sales rising 13 percent.
Qiagen posted revenues of $396.9 million in Q4 compared to $366.5 million a year ago and beat analysts' estimates on both the top and bottom lines.
The company's full year revenues increased 14 percent over 2016, to $20.92 billion.
The company reported Q4 and full-year 2017 revenues of $778.0 million and $2.75 billion, respectively.
Revenues in PerkinElmer's diagnostics business rose 23 percent in Q4, thanks largely to its acquisition of autoimmune diagnostic testing firm Euroimmun.
An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.